Combining standard adjuvant chemotherapy with the immune checkpoint inhibitor atezolizumab [Tecentriq] leads to a significant improvement in disease-free survival in a subset of patients with Stage ...

Results from the Phase III SERENA-6 clinical trial found that switching to treatment with camizestrant if an ESR1 mutation is detected during first-line treatment can help slow cancer growth for ...

A pre-surgical combination therapy including pembrolizumab [Keytruda] plus dabrafenib [Tafinlar] and trametinib [Mekinist] (DTP) significantly improved survival in patients with rare BRAF ...

The number of people living with a history of cancer in the United States is estimated at 18.6 million as of January 1, 2025 and projected to exceed 22 million by 2035, according to a new report, ...

Kelly Bolton St. Louis, Missouri To help prevent blood cancers, Kelly Bolton, MD, PhD, an oncologist and epidemiologist at the University of Washington Medical School, is leading clinical trials for ...

People who are overweight or obese are at higher risk for at least 13 different types of cancer, which together make up about 40 percent of all cancer diagnoses in the United States, according to the ...

People who used GLP-1 receptor agonists, like Ozempic, had a modestly lower risk for obesity-related malignancies, especially colon and rectal cancer.

Chemotherapy doesn’t just kill cancer cells. It also affects the microbes in the digestive tract. Researchers at UC San Francisco have discovered that some gut bacteria can reduce the side effects of ...

Cancer develops when cells grow out of control. Lung cancer begins in the lungs and can spread to the lymph nodes and elsewhere in the body, a process known as metastasis. Lung cancer is often ...

Breast cancer received the most funding by far, at $460 million, accounting for a third of all cancer-specific nonprofit revenue. Next in line—with less than half the funding of breast cancer—were ...

On May 15, the Food and Drug Administration (FDA) approved Zynyz (retifanlimab) immunotherapy for people with advanced anal cancer based on promising results from a late-stage clinical trial. This ...

Welcoming participants to the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place this week Chicago, ASCO CEO Clifford Hudis, MD, acknowledged the detrimental effects of ...